Novartis’ $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

All NewsJune 11, 2026

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT